Metabolic alterations mediated by STAT3 promotes drug persistence in CML.

Leukemia
Sweta B PatelRobert Welner

Abstract

Leukemic stem cells (LSCs) can acquire non-mutational resistance following drug treatment leading to therapeutic failure and relapse. However, oncogene-independent mechanisms of drug persistence in LSCs are incompletely understood, which is the primary focus of this study. We integrated proteomics, transcriptomics, and metabolomics to determine the contribution of STAT3 in promoting metabolic changes in tyrosine kinase inhibitor (TKI) persistent chronic myeloid leukemia (CML) cells. Proteomic and transcriptional differences in TKI persistent CML cells revealed BCR-ABL-independent STAT3 activation in these cells. While knockout of STAT3 inhibited the CML cells from developing drug-persistence, inhibition of STAT3 using a small molecule inhibitor sensitized the persistent CML cells to TKI treatment. Interestingly, given the role of phosphorylated STAT3 as a transcription factor, it localized uniquely to genes regulating metabolic pathways in the TKI-persistent CML stem and progenitor cells. Subsequently, we observed that STAT3 dysregulated mitochondrial metabolism forcing the TKI-persistent CML cells to depend on glycolysis, unlike TKI-sensitive CML cells, which are more reliant on oxidative phosphorylation. Finally, targeting py...Continue Reading

References

Oct 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sven GottschalkNatalie J Serkova
Jan 10, 2009·Science·Joanna WegrzynAndrew C Larner
Apr 30, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Douglas J KominskyNatalie J Serkova
May 20, 2009·Bioinformatics·Heng Li, Richard Durbin
Jun 10, 2009·Bioinformatics·Heng LiUNKNOWN 1000 Genome Project Data Processing Subgroup
Dec 30, 2009·The Journal of Clinical Investigation·Ismael SamudioMichael Andreeff
Mar 5, 2010·EMBO Molecular Medicine·Andrea HoelblVeronika Sexl
Dec 16, 2010·The Journal of Clinical Investigation·Amie S CorbinBrian J Druker
Nov 22, 2011·Nature·Christian M MetalloGregory Stephanopoulos
Aug 1, 2013·Nature Communications·Sarah-Maria FendtGregory Stephanopoulos
Apr 4, 2014·Bioinformatics·Anthony M BolgerBjoern Usadel
May 7, 2014·Nucleic Acids Research·Fidel RamírezThomas Manke
Jun 25, 2015·Frontiers in Oncology·Valeria Poli, Annalisa Camporeale
Mar 24, 2016·Nature Communications·Deepak BarariaDaniel G Tenen
Feb 6, 2017·Blood·Tessa L Holyoake, David Vetrie
Mar 9, 2017·The New England Journal of Medicine·Andreas HochhausUNKNOWN IRIS Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.